News from the Broad

The Broad Institute is committed to open sharing not only of its scientific data and tools, but also information and news about our progress towards achieving our mission. Below are just a few highlights from the Broad scientific community.
  • Broad Institute-MIT team identifies highly efficient new Cas9 for in vivo genome editing

    April 1st, 2015
    New finding is expected to expand therapeutic and experimental applications of CRISPR
    Read Full Story
  • Broad Institute of MIT and Harvard and Bayer Healthcare expand their partnership to develop therapies for cardiovascular disease

    March 31st, 2015
    The Broad Institute of MIT and Harvard have expanded their collaboration with Bayer HealthCare to include cardiovascular genomics and drug discovery. The goal of this new part of the alliance is to leverage insights from human genetics to help create new cardiovascular therapies.
    Read Full Story
  • Findings help unravel lung cancer drug resistance

    March 18th, 2015

    One of the primary limitations to the effectiveness of cancer therapeutics is drug resistance. This month in the journal Cell, Broad researchers Rick Wilson, Levi Garraway, and colleagues describe their work unraveling drug resistance mechanisms for ALK tyrosine kinase inhibitors in ALK-dependent non-small cell lung cancers. They screened nearly 16,000 ORFs corresponding to over 12,000 genes, identifying a range of known mechanisms able to confer resistance to ALK inhibitors, along with new ones including purinergic P2Y receptors (G-protein coupled receptors) acting through Protein Kinase C signaling.

  • Broad Institute and Calico announce an extensive collaboration focused on the biology of aging and therapeutic approaches to diseases of aging

    March 17th, 2015
    The Broad Institute of MIT and Harvard has entered into a partnership with Calico around the biology and genetics of aging and early-stage drug discovery. The partnership will support several efforts at the Broad to advance the understanding of age-related diseases and to propel the translation of these findings into new therapeutics.
    Read Full Story
  • Researchers validate the use of stool samples for microbiome studies

    March 16th, 2015

    Scientists studying the human gut microbiome often analyze stool to measure what’s living in the gut. However, they were uncertain how well those samples represented the microbial make-up of the intestine. Reporting in Cell Host & Microbe, a team led by Curtis Huttenhower and Xochitl Morgan of the Broad Institute and Harvard T. H. Chan School of Public Health used 16S sequencing to compare the microbial composition in stool with that found in the intestines of rhesus macaques. The team discovered that microbial communities found in feces correlated highly with those found in the large intestines and moderately with those of the small intestines, supporting the use of stool in microbiome studies.